An Open-Label Safety Study to Assess the Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Topical Treatment With Halobetasol Propionate 0.05% Topical Spray (Sun Pharmaceuticals Industries Limited) in Patients With Moderate to Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Ulobetasol (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Sun Pharmaceutical Industries
- 15 Feb 2018 Status changed from active, no longer recruiting to suspended.
- 19 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Aug 2017 New trial record